Annual report pursuant to Section 13 and 15(d)

Note 25 - Selected Quarterly Financial Data (Unaudited)

v3.8.0.1
Note 25 - Selected Quarterly Financial Data (Unaudited)
 12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Quarterly Financial Information [Text Block]
2
5
.
Selected Quarterly Financial Data (Unaudited)
 
Quarterly financial information for fiscal
201
7
and
2016
are presented in the following table, in thousands, except per share data. Certain revenue and expense amounts in the years ended
December 31, 2017
and
2016
have been reclassified to discontinued operations. See Note
3.
 
   
For the Quarter Ending
  
   
March 31
    
June 30
    
September 30
    
December 31
  
2017:
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
Tc99m tilmanocept sales revenue
   $
—
     $
—
     $
—
     $
—
  
Tc99m tilmanocept license revenue
    
—
      
100
      
—
      
—
  
Tc99m tilmanocept royalty revenue
    
—
      
—
      
—
      
9
  
Grant and other revenue
    
580
      
512
      
224
      
386
  
Gross profit
    
580
      
612
      
224
      
391
  
Operating expenses
    
3,728
      
5,435
      
2,609
      
3,912
  
Loss from operations
    
(3,148
)
    
(4,823
)
    
(2,385
)
    
(3,521
)
Loss before income taxes
    
(4,319
)
    
(4,783
)
    
(2,317
)
    
(6,371
)
Benefit from
(provision for) income taxes
    
1,454
      
1,631
      
776
      
201
  
Loss from continuing operations
    
(2,865
)
    
(3,152
)
    
(1,541
)
    
(6,170
)
Gain (loss) from discontinued operations, net of tax
    
88,446
      
(2,036
)
    
151
      
2,112
  
Net
income (loss) attributable to common stockholders
    
85,581
      
(5,188
)
    
(1,390
)
    
(4,058
)
Loss per common share (basic)
(1)
:
                                
Continuing operations
   $
(0.02
)
   $
(0.02
)
   $
(0.01
)
   $
(0.04
)
Discontinued operations
   $
0.55
     $
(0.01
)
   $
—
     $
0.01
  
Attributable to common stockholders
   $
0.53
     $
(0.03
)
   $
(0.01
)
   $
(0.03
)
Loss per common share (diluted)
(1)
:
                                
Continuing operations
   $
(0.02
)
   $
(0.02
)
   $
(0.01
)
   $
(0.04
)
Discontinued operations
   $
0.54
     $
(0.01
)
   $
—
     $
0.01
  
Attributable to common stockholders
   $
0.52
     $
(0.03
)
   $
(0.01
)
   $
(0.03
)
                                 
2016:
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
Tc99m tilmanocept sales revenue
   $
9
     $
4
     $
18
     $
9
  
Tc99m tilmanocept license revenue
    
254
      
246
      
1,296
      
—
  
Grant and other revenue
    
686
      
917
      
511
      
1,022
  
Gross profit
    
947
      
1,166
      
1,821
      
975
  
Operating expenses
    
4,705
      
3,407
      
2,731
      
4,215
  
Loss from operations
    
(3,758
)
    
(2,241
)
    
(910
)
    
(3,240
)
Loss from continuing operations
    
(2,682
)
    
(817
)
    
(1,761
)
    
(2,118
)
Gain (loss) from discontinued operations, net of tax
    
(1,004
)
    
(5,865
)
    
1,702
      
(1,764
)
Net loss attributable to common stockholders
    
(3,686
)
    
(6,682
)
    
(59
)
    
(3,882
)
Loss per common share (basic and diluted)
(1)
:
                                
Continuing operations
   $
(0.02
)
   $
(0.01
)
   $
(0.01
)
   $
(0.01
)
Discontinued operations
   $
0.00
     $
(0.03
)
   $
0.01
     $
(0.02
)
Attributable to common stockholders
   $
(0.02
)
   $
(0.04
)
   $
(0.00
)
   $
(0.03
)
 
 
(
1
)
Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will
not
necessarily equal the annual per share calculation.